Area: Evidence > Drug Specific Reviews
The North East Treatment Advisory Group (NETAG) has produced an updated appraisal of bevacizumab for the management of neovascular age-related macular degeneration and recommended bevacizumab 1.25 mg intravitreal injection as cost effective treatment option for this condition. The group was satisfied that the relative clinical efficacy and safety of bevacizumab for AMD had been adequately demonstrated.
It should be noted that bevacizumab is not licensed for any ophthalmic indication. Ranibizumab is licensed for wet age-related macular degeneration and there is NICE (Read more...)